Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Share option exercises and awards
Manchester, UK - 23 March 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces an exercise and an additional award of share options.
Exercise of options
The Company has received notification for the following exercise of options, generating in aggregate proceeds of approximately £205,000 ("Options Exercise") to the Company:
| | Number of options exercised | Exercise price |
| | 320,000 | 10.00 pence |
| | 33,333 | 10.25 pence |
| | 2,200,000 | 7.75 pence |
| Total: | 2,553,333 | |
Application will be made to the London Stock Exchange to admit the 2,553,333 new ordinary shares resulting from the Options Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 26 March 2021. The new ordinary shares will rank pari passu with the existing ordinary shares.
Award of options
The Company has today issued 1,400,000 options over Ordinary Shares of 0.1p under the Company's Enterprise Management Incentive (EMI) and unapproved share option schemes to a number of individuals to reflect recent management changes.
In addition to the above, the Company has identified an administrative error which occurred in the award of 750,000 options announced on 25 September 2020, and a further 400,000 options issued and announced on 19 June 2020. These 1,150,000 options have been cancelled and reissued with identical terms.
| | Options granted 22 March 2021 | 2020 EMI Options cancelled & reissued | Total options now granted |
| Dr Joanne Mason* | 250,000 | 750,000 | 1,000,000 |
| Other | 1,150,000 | 400,000 | 51,359,232 |
| Total | 1,400,000 | 1,150,000 | 61,359,232 |
*Dr Joanne Mason is a director of the Company.
The options are exercisable in three tranches over three financial years and are subject to certain performance conditions. The options awarded on 22 March 2021 are exercisable up to 21 March 2031, at a price of 18 pence per share.
Total Voting Rights
For the purpose of the Disclosure and Transparency Rules, following the issue of shares to satisfy exercised share options detailed above the enlarged issued share capital of the Company will comprise 723,063,283 ordinary shares of 0.1p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.
Following the award of these new options, and taking into account lapsed options and those cancelled and reissued, the Company has 61,359,232 shares under option, a further 54,332,541 shares under warrant to Thermo Fisher and 10,249,624 shares in a Canadian subsidiary which are exchangeable for shares in the Company. The Company's investor website provides details of these warrants and exchangeable shares.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
| Yourgene Health plc Lyn Rees, Chief Executive Officer | Tel: +44 (0)161 669 8122 | |||
| Barry Hextall, Chief Financial Officer | | |||
| Joanne Cross, Director of Marketing | | |||
| | | |||
| Cairn Financial Advisers LLP (NOMAD) | Tel: +44 (0)20 7213 0880 | |||
| Liam Murray / James Caithie / Ludovico Lazzaretti |
| |||
| N+1 Singer (Joint Corporate Broker) | Tel: +44 (0)20 7496 3000 | |||
| Aubrey Powell / Tom Salvesen / George Tzimas | | |||
| | | |||
| Stifel Nicolaus Europe Limited (Joint Corporate Broker) | Tel: +44 (0)20 7710 7600 | |||
| Nicholas Moore / Matthew Blawat / Ben Maddison | | |||
| | | |||
| Walbrook PR Ltd (Media and Investor Relations) | Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com | |||
| Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / Mob: 07584 391 303 | |||
| | | |
| |
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
| Dr Joanne Mason
| |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| Director | |||
| b)
| Initial notification /Amendment
| Initial notification | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
| a)
| Name
| Yourgene Health plc | |||
| b)
| LEI
| 213800UUIT8BZE7QEH33 | |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
| a)
| Description of the financial instrument, type of instrument | Options over ordinary shares of 0.1p each | |||
| | | ||||
| Identification code | ISIN: GB00BN31ZD89 | ||||
| | | ||||
| b)
| Nature of the transaction
| Grant of options | |||
| c)
| Price(s) and volume(s) | | | | |
| | | Price(s) | Volume(s) | | |
| | | 7.75p 18.0p | 250,000 750,000 | | |
| | | | | | |
| d)
| Aggregated information | | |||
| | | ||||
| - Aggregated volume | 1,000,000 | ||||
| | | ||||
| - Price | 7.75p / 18.0p | ||||
| | | ||||
| e)
| Date of the transaction
| 22 March 2021 | |||
| f)
| Place of the transaction
| UK | |||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
